Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listApremilast

Apremilast

  • CAS NO.:608141-41-9
  • Empirical Formula: C22H24N2O7S
  • Molecular Weight: 460.5
  • MDL number: MFCD18782607
  • EINECS: 807-237-6
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 23:02:33
Apremilast Structural

What is Apremilast?

Absorption

An oral dose of apremilast is well-absorbed and the absolute bioavailability is approximately 73%. Tmax is approximately 2.5 hours and Cmax has been reported to be approximately 584 ng/mL in one pharmacokinetic study. Food intake does not appear to affect apremilast absorption.

Toxicity

The oral LD50 in mice was greater than 2000 mg/kg in mice. In rats, oral LD50 was 2000 mg/kg males and 300 mg/kg in females.
Overdose information
In healthy subjects receiving a maximum dose of 100 mg (given as 50 mg twice daily) for about 5 days, no significant toxicity was observed. In cases of an overdose, supportive and symptomatic treatment should be administered. Contact the local poison control center for the most recent overdose management for apremilast.

Description

Apremilast is the first and only oral phosphodiesterase IV (PDE- 4) inhibitor and anti-tumor necrosis factor alpha (TNFa) agent launched in the USA by Celgene for the treatment of active psoriatic arthritis (PsA). Apremilast was also approved for the treatment of moderate to severe plaque psoriasis in the USA. Later, this drug was also approved in the European Union (EU) for both indications. Although multiple approaches to the synthesis of apremilast have been described, the most likely process scale approach involves the construction of the challenging stereogenic benzylic carbon center by catalytic asymmetric hydrogenation.

The Uses of Apremilast

Apremilast is an oral phosphodiesterase 4 inhibitor used in the treatment of adults with active psoriatic arthritis and adults with moderate to severe plaque psoriasis.

Indications

Apremilast is indicated for the treatment of adults with active psoriatic arthritis and adults with oral ulcers associated with Behcet's Disease. In addition, apremilast is indicated for the treatment of plaque psoriasis, of any severity, in adult patients who are candidates for phototherapy or systemic therapy.

Background

Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole. Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.

Definition

ChEBI: Apremilast is a member of the class of isoindoles that is isoindole-1,3-dione substituted at position 4 by an acetamido group and at position 1 by a 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl group. Used for treatment of psoriatic arthritis. It has a role as a phosphodiesterase IV inhibitor and a non-steroidal anti-inflammatory drug. It is an aromatic ether, a N-acetylarylamine, a sulfone and a member of phthalimides.

Pharmacokinetics

Apremilast reduces but does not completely inhibit various inflammatory cytokines such as IL-1α, IL-6, IL-8, IL-10 MCP-1, MIP-1β, MMP-3, and TNF-α, relieving the symptoms of psoriasis and Behcet's disease, which are caused by an increase in these inflammatory mediators. This drug has also been proven to be effective in relieving the pain associated with oral ulcers in Behcet's disease.
Apremilast may cause unwanted weight loss and worsen depression, leading to suicidal thoughts or actions. It is advisable to monitor for symptoms of depression and seek medical attention if they occur, especially in patients with pre-existing depression. The need for apremilast should be carefully assessed along with the risk of worsening depression and suicide. If weight loss occurs, the degree of weight loss should be evaluated, and consideration should be made for the possible discontinuation of apremilast.

Clinical Use

Treatment of active psoriatic arthritis (PsA) and moderate to severe chronic plaque psoriasis (PSOR)

Synthesis

Dimethyl sulfone was first subjected to n-butyllithium in tetrahydrofuran (THF) prior to exposure to commercially available 3-ethoxy-4-methoxybenzonitrile (15) at low temperature to afford enamine 16 in 83% yield, presumably as a single isomer enamine possessing the E-configuration. After considerable studies conducted by researchers at Celgene regarding the reduction of this enamine and alternative substrates, enamine 16 was reduced under asymmetric hydrogenation conditions consisting of [Rh (COD)2]OTf and (S,R)-t-Bu Josiphos in trifluoroethanol (TFE) at 50 ?? under 90 psi of hydrogen pressure. Immediate exposure of the product to N-acetyl-L-leucine in methanol afforded the corresponding benzylamine salt 18 in 80% yield and more than 99% enantiomeric excess (ee). Finally, compound 18 was condensed with commercially available N-(phthalimid-3-yl)acetamide (19) in refluxing acetic acid to provide apremilast (III) in 83% yield and 99.4% ee.

Synthesis_608141-41-9

Overdosage

Apremilast was studied in healthy subjects at a maximum total daily dose of 100 mg (given as 50 mg twice daily) for 4.5 days without evidence of dose limiting toxicities. In case of an overdose, it is recommended that the patient is monitored for any signs or symptoms of adverse effects and appropriate symptomatic treatment is instituted. In the event of overdose, symptomatic and supportive care is advised.

Enzyme inhibitor

This thalidomide-like psoriasis drug (FW = 460.50 g/mol; CAS 608141-41-9; Solubility: 90 mg/mL DMSO; <1 mg/mL H2O), also known as CC-10004, Otezla? and N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl-sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide, is a potent, orally active phosphodiesterase inhibitor that targets phosphodiesterase PDE4 (IC50 = 74 nM), itself a proinflammatory mediator, and TNF-α, IC50 = 77 nM. Apremilast inhibits PBMC production of the chemokines CXCL9 and CXCL10, cytokines interferon-γ and tumor necrosis factor-α (TNF-α), and interleukins IL-2, IL-12 and IL- 23 from human rheumatoid synovial membrane cultures. Apremilast significantly reduces clinical scores in both murine models of arthritis over a ten-day treatment period and maintains healthy joint architecture in a dose-dependent manner. Unlike rolipram, however, apremilast demonstrated no adverse behavioral effects in na?ve mice. Otezla is specifically indicated by the Food & Drug Administration for the treatment of patients with moderate to severe plaque psoriasis who are typically candidates for phototherapy or systemic therapy. That said, the specific mechanism(s) for therapeutic action in psoriatic arthritis patients and psoriasis patients is unclear.

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: concentration reduced by rifampicin - avoid.
Antidepressants: concentration possibly reduced by St John’s wort - avoid.
Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone - avoid.

Metabolism

Apremilast is extensively metabolised by both CYP and non-CYP mediated pathways including oxidation, hydrolysis, and conjugation, suggesting inhibition of a single clearance pathway. After oral administration of radiolabelled apremilast, about 3% and 7% of the radioactive dose is recovered as apremilast in urine and faeces, respectively.

Metabolism

Apremilast is heavily metabolized by various pathways, which include oxidation, hydrolysis, in addition to conjugation. About 23 metabolites are produced from its metabolism. The CYP3A4 primarily mediates the oxidative metabolism of this drug, with smaller contributions from CYP1A2 and CYP2A6 enzymes. The main metabolite of apremilast, M12, is an inactive glucuronide conjugate form of the O-demethylated drug. Some other major metabolites, M14 and M16, are significantly less active in the inhibition of PDE4 and inflammatory mediators than their parent drug, apremilast. After an oral dose, unchanged apremilast (45%) and the inactive metabolite, O-desmethyl apremilast glucuronide (39%) are found in the plasma. Minor metabolites M7 and M17 are active, but are only present in about 2% or less of apremilast concentrations, and likely not significant contributors to the actions of apremilast.

Mode of action

Apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-α, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. These pro- and anti-inflammatory mediators have been implicated in psoriatic arthritis and psoriasis.

Properties of Apremilast

Melting point: 152-156°C
Boiling point: 741.3±60.0 °C(Predicted)
Density  1.381
storage temp.  Refrigerator
solubility  Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly, Heated)
form  Solid
pka 14.01±0.20(Predicted)
color  White to Pale Yellow
CAS DataBase Reference 608141-41-9

Safety information for Apremilast

Computed Descriptors for Apremilast

InChIKey IMOZEMNVLZVGJZ-QGZVFWFLSA-N
SMILES C(NC1=CC=CC2=C1C(=O)N([C@@H](C1=CC=C(OC)C(OCC)=C1)CS(C)(=O)=O)C2=O)(=O)C

Abamectin manufacturer

KARPSCHEM LABORATORIES PVT. LTD.

1Y
Phone:+917249203006
Whatsapp: +91 7249203006
product: 608141-41-9 Apremilast (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl) -2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide 96%
Inquiry

Varanous Labs Pvt Ltd

1Y
Phone:+917036248882
Whatsapp: +91 7036248882
product: 608141-41-9 98%
Inquiry

NEULAND LABS

1Y
Phone:+914067611600
product: Apremilast 98%
Inquiry

Metrochem API Private Limited

1Y
Phone:+91-4069069999
product: Apremilast 98%
Inquiry

Lupin Ltd

1Y
Phone:+91-8019896181
Whatsapp: +91 8019896181
product: 608141-41-9 Apremilast 99%
Inquiry

Alembic Pharmaceuticals Limited

1Y
Phone:+912652280550
product: 608141-41-9 98%
Inquiry

Aurobindo Pharma Limited

1Y
Phone:+91-4066725000
product: Apremilast 98%
Inquiry

Glenmark Pharmaceuticals Limited

1Y
Phone:+912240189999
product: Apremilast 608141-41-9 98%
Inquiry

Hetero Drugs Limited

1Y
Phone:+914023704923
product: 608141-41-9 Apremilast 98%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.